Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Immunovant, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Immunovant, Inc. (“Immunovant” or “the Company”) (NASDAQ: IMVT). Investors who purchased Immunovant securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Immunovant has violated federal securities laws.
Immunovant Investigation Details
On September 23, 2026, Immunovant announced that its proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus did not achieve statistical significance on its primary endpoint. The company said it plans to stop developing the drug for that indication. Following the announcement, Immunovant ‘s stock price dropped 7.37% on September 23, 2026.
What’s Next for Immunovant Investors?
If you are aware of any facts relating to this investigation or purchased Immunovant securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
IMVT — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”